FilingReader Intelligence
Livzon's psoriasis drug meets phase III trial endpoint
July 21, 2025 at 05:18 PM UTC•By FilingReader AI
Livzon Pharmaceutical Group announced its LZM012 drug met its primary endpoint in phase III trials for moderate to severe plaque psoriasis.
At week 12, LZM012 showed a 49.5% response rate, demonstrating superiority to the control group's 40.2%. The company has filed for market approval.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:000513•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Livzon Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime